Last checked at 17 Feb 2016 16:57
17 February 2016 | AIM: RENE |
ReNeuron Group plc
Director's Dealings
Guildford, UK, 17 February 2016: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, announces that on 3 February 2016, Michael Hunt, Chief Financial Officer, instructed the cashless exercise of options over 5,361,673 ordinary shares of 1p each in the Company at an exercise price of £0.01 per share. The following table sets out the relevant share sales that were required to achieve the cashless exercise and satisfy the exercise price, pay relevant taxes and retain 250,000 shares.
Trade date |
Share price (£) | Number of shares |
05/02/2016 | 0.030000 | 1,035,533 |
11/02/2016 | 0.029307 | 1,208,333 |
12/02/2016 | 0.028000 | 594,637 |
17/02/2016 | 0.028089 | 509,554 |
17/02/2016 | 0.028000 | 1,763,616 |
As a result of the recent exercises and share transactions, completed today, Mr Hunt's interest in ordinary shares has increased to 1,758,471 ordinary shares, representing approximately 0.06% per cent. of the Company's issued share capital.
Following the issue of 5,361,673 ordinary shares pursuant to the exercise of options described above, the Company's issued share capital is now 3,164,618,541. The Company holds no ordinary shares in treasury. The above figure of 3,164,618,541 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan |
+44 (0) 20 7466 5000 |
Mark Court, Sophie Cowles, Stephanie Watson | |
Cenkos Securities | +44 (0) 20 7397 8900 |
Stephen Keys, Dr Christopher Golden (NOMAD and Broker) | |
Russell Kerr (Sales) |
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.